Next Investors logo grey

Cellmid records highest ever quarterly sales for Evolis®

Published 11-OCT-2016 09:18 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Cellmid Limited (ASX:CDY) launched its Evolis® range of professional anti-aging hair care products in Australia in June this year. Today, the company reported that since launch its product range has clocked up an impressive $1,022,913 in sales for Q1 FY2017.

The company has exceeded its aim to reach a million dollars in sales, exceeding the limit comfortably by $22,000 – an excellent start to the 2017 financial year.

The Evolis® range of hair care products is sold through the company’s wholly owned subsidiary Advangen Limited, which sell a distinctive FGF5 inhibitor product for hair loss.

The reason for these strong results could be Cellmid’s new regional advertising program, as website sales grow and the company see social and digital marketing campaigns deliver returns.

Overall, sales were up by 30 per cent compared with the same period in FY2016. And that’s before the products hit the US market – which is next on the list, with commencement of US sales expected to occur in Q2 FY2017.

Cellmid is a biotechnology company which operates across life sciences and also develops and markets innovative and novel therapies, as well as diagnostic tests, for fibrotic diseases, cancer ischemic diseases of the heart and for hair loss.

The company generates millions of dollars of revenue through its hair loss business, Advangen, backed by a strong foundation of intellectual property relating to FGF5.

These products were already available in Japan before their recent launch in Australia. They’re designed not just to prevent hair loss and increase hair growth, but also maximise scalp health and hair condition.

Between FY2014, when Cellmid acquired Advangen Inc, and FY2016, sales increased by 171 per cent. 2016 was the first financial year Advangen were able to claim as profitable. Along the way the company has seen growth not just in revenue, but in profitability, with normalised income cover growing from 37 to 57 per cent in the same timeframe.

This level of growth is not guaranteed to continue and investors should seek professional financial advice if considering CDY for their portfolio.

The push for sales shows no sign of slowing, as CDY eagerly look to grow the business, and increase profits, by developing their product footprint globally.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.